Synageva BioPharma
Corporate Offices
128 Spring Street, Suite 520
Lexington
Massachusetts
02421
United States
Tel: 781-890-1111
Fax: 781-890-1114
Website: http://www.synageva.com/
Email: info@synageva.com
About Synageva BioPharma
Synageva BioPharma is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and unmet medical need. Our lead program, SBC-102, an enzyme replacement therapy for LAL Deficiency, is currently being evaluated in global Phase I/II clinical trials. SBC-102 has been granted orphan designations by the U.S. Food and Drug Administration (“FDA”) and the European Medicines Agency and fast track designation by the FDA. Synageva has several protein therapeutics focused on life threatening conditions in its pipeline. The Company has assembled a team with a proven record of bringing orphan therapies to patients.127 articles about Synageva BioPharma
-
Synageva BioPharma to Present at the Morgan Stanley Global Healthcare Conference
9/3/2013
-
Synageva BioPharma Reports Second Quarter 2013 Financial Results and Announces Appointment of Chief Operating Officer
8/6/2013
-
Synageva BioPharma to Present at the Goldman, Sachs & Co. and Wells Fargo Healthcare Conferences
6/5/2013
-
Synageva BioPharma Announces Presentations and a Satellite Symposium at the National Lipid Association Meeting
5/31/2013
-
Synageva BioPharma to Present at the Jefferies and Co. 2013 Global Healthcare Conference
5/23/2013
-
Synageva BioPharma's Sebelipase Alfa Receives Breakthrough Therapy Designation for Early Onset LAL Deficiency From the FDA
5/20/2013
-
Synageva BioPharma Joins the International MPS Network in Support of MPS Awareness Day 2013
5/15/2013
-
Synageva BioPharma Reports First Quarter 2013 Financial Results
5/8/2013
-
Synageva BioPharma Execs Got 28 Pct Compensation Hike in 2012
4/26/2013
-
Synageva BioPharma Release: Late Onset LAL Deficiency (CESD) Literature Review Published in the Journal of Hepatology
3/26/2013
-
Synageva BioPharma Reports 2012 Full Year Financial Results
3/12/2013
-
Synageva BioPharma to Host 2012 Fourth Quarter and Full Year Financial Results Conference Call on March 11
3/4/2013
-
Synageva BioPharma to Present at the Cowen and Company 33rd Annual Health Care Conference
2/26/2013
-
Synageva BioPharma Initiates Dosing in Phase 3 Trial of Sebelipase Alfa in Children and Adults Wth Late Onset LAL Deficiency
2/11/2013
-
Synageva BioPharma to Present at the Leerink Swann and Company Global Healthcare Conference 2013
2/7/2013
-
Synageva BioPharma Release: Hepatology Publishes 12-Week Phase I/II Extension Study Data of Sebelipase Alfa in Adults With Late Onset LAL Deficiency
2/5/2013
-
Synageva BioPharma Announces Closing of Public Offering and Exercise of Option to Purchase Additional Shares
1/9/2013
-
Synageva BioPharma Announces Pricing of Public Offering of Common Stock
1/4/2013
-
Synageva BioPharma Announces $80 Million Proposed Public Offering of Common Stock
1/3/2013
-
Synageva BioPharma to Present at the 31st Annual J.P. Morgan Healthcare Conference
12/20/2012